The mRNA Bandwagon - Part I
Fallout from the COVID-19 disaster is ongoing, and humanity is being called to understand and respond to the urgent situation we find ourselves in. Dr. Philip McMillan has recently broadcast an excellent interview with radiologist Phillip Triantos MD, from the US, and general practitioner Shankara Chetty MD, from South Africa. These three doctors expose the smoking gun in the life-threatening aftermath of the COVID-19 injections:
Like other radiologists and embalmers around the world, Dr. Triantos is seeing on a daily basis large, white, rubbery clots within the vasculature of people who took the COVID-19 injections. The clots take the shape of the vessels they are growing in, and although they are not made of biological material, can “grow” to enormous proportions, such as the length of the entire leg. Dr. Chetty gives the insightful analogy that the clots are like streamers, attached at one end and then flapping inside blood vessels, much like a streamer would flap in the wind. In this way blood can continue to flow around the large, synthetic clots until vessels are completely occluded.
The plastic-like structures are not only the most shocking and horrifying symptom of vax-injury, they are the smoking gun, the incontrovertible and incriminating evidence that the bodies of billions of people around the world have been severely poisoned.
The white clots are the “ground”, the foundation from which all analyses of vaccine contents and mechanisms-of-action must be considered. Yet, many of the world’s top health-freedom doctors and scientists, such as Peter McCullough MD, and Geert Vanden Bossche PhD, rarely mention the most obvious and salient feature of the COVID-19 massacre.
Although I do not have a reference for this, I clearly remember Dr. McCullough saying early on in the pandemic (and I paraphrase), “mRNA is a failed technology. No way could synthetic mRNA be turned into spike protein.” Dr. McCullough is a highly credentialed cardiologist and researcher. Why didn’t he take his line of reasoning further and look more deeply into the published literature? Instead, he started a multi-million dollar supplement company, and his Spike Support Formula is the company’s leading product. Had McCullough done his homework, he would’ve soon learned that indeed, mRNA could not possibly be responsible for the white, rubbery clots filling the vasculature of the vaccinated.
mRNA is the intermediate step between the transcription of protein-encoding DNA and the production of proteins inside tiny machines called ribosomes, which exist within the cytoplasm, or gel-like interior of the cell. Conventional mRNA-based vaccines, such as the Pfizer and Moderna COVID-19 injections, are made of five components: a 5′ cap, a 5′ untranslated region (UTR), an open reading frame (ORF) encoding the antigen of interest (“spike protein”), a 3′ UTR and a 3′ polyadenosine (poly(A)) tail.1 These five elements mimic the structure of eukaryotic mRNA, and thus are engineered to resemble fully processed mRNA molecules as they occur naturally in the cytoplasm of the cell.
Not all regions of the mRNA molecule correspond to particular amino acids. The 5' UTR is the non-protein-coding section of the mRNA that is located between the 5' end and the ORF, or coding region. The 3' UTR is the non-protein-coding section of mRNA that is found between the coding region and the poly(A) tail. These UTRs are believed to play important roles in mRNA processing, transport, stability, and translation, yet they cannot be reproduced or mimicked because they are kept secret by Nature.
Scientists know that the 5′ UTR plays a crucial role in regulating protein expression. Yet, control over mRNA expression cannot be achieved until the active genetic sequences within UTRs are identified, as well as the cellular factors that interact with these genetic elements.2
“A comprehensive systems biology approach to gene regulation will require that we systematically identify active sequences within UTRs (cis elements), identify the cellular trans factors that interact with these cis elements, and determine the functional consequences of these interactions.”3
UTRs are one of the main reasons synthetic, modified mRNA, such as that used in the COVID shots, are recognized as non-self nucleic acids by mammalian cells.4 This makes exogenous mRNA inherently immunogenic and swiftly cleared from the body, as it is recognized by a variety of cell surface, endosomal, and cytosolic innate immune receptors.5 The lipid nanoparticles (LNPs) used to encase the mRNA are highly immunogenic as well, but even if a cell does begin to take an LNP inside by enveloping it into part of the cell membrane (an endosome), there is little chance the mRNA will escape into the cytosol to be translated into protein.
This fact has been well-understood since the inception of LNP technology. The COVID-19 mRNA shots use the same LNP formulation as the small interfering RNA (siRNA) drug Onpratto®, approved by the FDA in 2018. Yet, in an important study published in the journal Nature Biotechnology in 2013, it was shown that less than 2% of LNP-delivered siRNA taken up by cells is released into the cytosol, and escape occurs only during a brief phase in the existence of the endosome.6 Astonishingly, in a 2023 study published in the Journal of the American Chemical Society, researchers clearly state,
“Lipid nanoparticles (LNPs) represent the most clinically advanced non-viral mRNA delivery vehicles; however, the full potential of the LNP platform is greatly hampered by inadequate endosomal escape capability.”7
A series of studies have been published over the past several decades claiming success of mRNA as gene therapy and vaccine technology. Robert Malone MD and colleagues proclaimed in 1990 that both naked mRNA and plasmid DNA could be injected into humans and readily translated into proteins.8 The scientific community was not convinced however,
“These early promising results did not lead to substantial investment in developing mRNA therapeutics, largely owing to concerns associated with mRNA instability, high innate immunogenicity, and inefficient in vivo delivery.”9
Today it is widely known that,
“Intracellular delivery is difficult for both naked mRNA and plasmid DNA as they are unstable and unable to enter target cells by themselves.”10
In 2015, Drew Weissman and Katalin Karikó published a study that would pave the way for the mRNA vaccines used against SARS-CoV-2,
“We have found that administration of mRNA-LNP complexes results in large amounts of protein production in vivo for varying lengths of time demonstrating that LNPs are suitable tools for highly efficient mRNA delivery…These studies will help to accelerate the transformation of mRNA therapeutics into clinical practice.”11
Weissman and Karikó claimed spectacular success in turning the mRNA-encoded enzyme luciferase into protein. The scientists synthesized the plasmid encoding modified luciferase themselves, and it was not revealed if any translation-enhancing sequences were contained in the plasmid vector.
However, a 2022 study showed that although LNP-encapsulated mRNA has been studied extensively, including several studies published on the formulation of the COVID-19 mRNA vaccines, these reports focus primarily on immune responses by measuring neutralizing antibody titers and T-cell activity.12 The researches cite the 2015 Weissman and Karikó study in particular,
“It is discovered that LNPs after intramuscular injection were not wholly constrained in the muscle tissue but became rapidly distributed throughout the body with a large presence in the liver. Importantly, the tissue expression of released mRNAs was not linearly correlated with the LNP accumulation.”13
The mRNA technology used in the COVID-19 vaccines is wrought with obstacles that have not been overcome. Two short years before the pandemic struck, Moderna was still struggling to create a successful LNP delivery vehicle. Only 15% of their best-performing LNPs succeeded in endosomal escape.14 Even as late as 2021 Moderna researchers were continuing to grapple with this problem.15 How then, could the mRNA/LNP technology possibly be the cause of the smoking gun, the large, self-perpetuating clots that are becoming ubiquitous in the world?
Clearly, the shots were a carefully orchestrated operation that most of the world’s population was not able to see through. Yet, if we do not wake up to what is really going on, we may be looking at an extinction-level event for the human species.
©️illustration by Ramona Snow Teo
Oh S Kessler J (2018). Design, Assembly, Production, and Transfection of Synthetic Modified mRNA. Methods 133: 29-43.
Chu, Y., Yu, D., Li, Y. et al. A 5′ UTR language model for decoding untranslated regions of mRNA and function predictions. Nat Mach Intell 6, 449–460 (2024). https://doi.org/10.1038/s42256-024-00823-9
Zhao W, Blagev D, Pollack JL, Erle DJ. Toward a systematic understanding of mRNA 3' untranslated regions. Proc Am Thorac Soc. 2011 May;8(2):163-6. doi: 10.1513/pats.201007-054MS. PMID: 21543795; PMCID: PMC3131834.
Oh 2018
Pardi N Hogan M Porter F Weissman D (2018). mRNA vaccines - a new era in vaccinology. Nature Reviews Drug Discovery 17(4): 261-279.
Gilleron J Querbes W Zeigerer A Borodovsky A Marsico G Schubert U Manygoats K Seifert S Andree C Stöter M (2013). Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nature Biotechnology 31: 638–646.
Chen Z Tian Y Yang J Wu F Liu S Cao W Xu W Hu T Siegwart D Xiong H (2023). Modular Design of Biodegradable Ionizable Lipids for Improved mRNA Delivery and Precise Cancer Metastasis Delineation In Vivo. Journal of the American Chemical Society 144(22): 9926–9937.
Wolff J Malone R Williams P Chong W Acsadi G Jani A Felgner P (1990). Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465-8.
Pardi 2018
Behr M Zhou J Xu B Zhang H (2021). In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. Acta Pharmaceutica Sinica B 11(8): 2150-2171.
Pardi N Tuyishime S Muramatsu H Kariko K Mui BL Tam Y Madden T Hope M Weissman D (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release 217: 345-51.
Di J Du Z Wu K et al (2022). Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. Pharmaceutical Research 39: 105–114.
Ibid
Sabnis S Kumarasinghe E Salerno T Mihai C ET AL (2018). A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Molecular Therapy 26(6): 1509-1519.
Cornebise M Narayanan E Xia Y Acosta E et al (2022). Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA. Advanced Functional Materials 32: 2106727.